About: Jinhua Qinggan granule, a Chinese herbal medicine against COVID-19, induces rapid changes in the plasma levels of IL-6 and IFN-Î³

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Jinhua Qinggan granule, a Chinese herbal medicine against COVID-19, induces rapid changes in the plasma levels of IL-6 and IFN-Î³ Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Jinhua Qinggan granule, a Chinese herbal medicine against COVID-19, induces rapid changes in the plasma levels of IL-6 and IFN-Î³
Creator	Aida, Koichi Akiyama, Tetsu Ebisui, Tomoka Kageyama, Yasunari Kawauchi, Kimihiko Morimoto, Masafumi Nakamura, Tsutomu
Source	MedRxiv
abstract	Background: Currently, effective vaccines or specific therapeutic agents against COVID-19 are not available. However, in China, traditional Chinese herbal medicines have provided therapeutic benefit to patients with COVID-19. Jinhua Qinggan granule (JHQGG) is a Chinese multi-herbal formula previously developed for the treatment of H1N1 influenza and has been encouraged for patients clinically suspected of COVID-19 during medical observation. However, the immunological mechanism for the efficacy of JHQGG has not been confirmed. Objectives: We thus examined whether the administration of JHQGG affects hematological and immunological measures in healthy individuals. Method: We enrolled 18 healthy volunteers, all of whom tested negative for antibodies to SARS-CoV-2. Peripheral blood samples were collected 1 h after oral administration of JHQGG and subjected to hematological, biochemical, and cytokine tests. Results: JHQGG rapidly induced a significant decrease in the plasma level of IL-6 and an increase in the plasma level of IFN-{gamma}. Conclusions: Our finding suggests that the therapeutic efficacy of JHQGG against COVID-19 is, in part, associated with its rapid immunomodulatory activity.
has issue date	2020-06-12(xsd:dateTime)
bibo:doi	10.1101/2020.06.08.20124453
has license	medrxiv
sha1sum (hex)	e431aceea4812785be3895db0e23cd34c444d59b
schema:url	https://doi.org/10.1101/2020.06.08.20124453
resource representing a document's title	Jinhua Qinggan granule, a Chinese herbal medicine against COVID-19, induces rapid changes in the plasma levels of IL-6 and IFN-Î³
resource representing a document's body	covid:e431aceea4812785be3895db0e23cd34c444d59b#body_text
is schema:about of	named entity 'THERAPEUTIC' named entity 'FORMULA' named entity 'BACKGROUND' named entity 'PREVIOUSLY' named entity 'China' named entity 'specific' named entity 'H1N1' named entity 'COVID-19' named entity 'However' named entity 'induces' named entity 'Chinese' named entity 'influenza' named entity 'traditional Chinese herbal medicines' named entity 'COVID-19' named entity 'China' named entity 'immunological' named entity 'Jinhua' named entity 'COVID-19' named entity 'vaccines' named entity 'therapeutic agents' named entity 'Chinese herbal medicine' named entity 'IFN-γ' named entity 'design of the study' named entity 'statistically significant' named entity 'confidence interval' named entity 'preprint' named entity 'IL-6' named entity 'mice' named entity 'COVID' named entity 'hematological' named entity 'influenza' named entity 'blood levels' named entity 'China' named entity 'IL-2 receptor' named entity 'IL-6' named entity 'preprint' named entity 'complete blood count' named entity 'tumor necrosis factor-α' named entity 'peer review' named entity 'IL-6' named entity 'clinical study' named entity 'H1N1' named entity 'inflammatory' named entity 'respiratory symptoms' named entity '0.01' named entity 'IFN' named entity 'plasma' named entity 'TNF-α' named entity 'immune dysregulation' named entity 'preprint' named entity 'IgM' named entity 'Ethics' named entity 'Beijing' named entity 'medRxiv' named entity 'CD4 +' named entity 'not-for-profit' named entity 'biochemical tests' named entity 'IFN-γ' named entity 'IFN-γ' named entity 'moderate cases' named entity 'peer review' named entity 'IFN-α/β' named entity 'IL-6' named entity 'Pharmaceutical' named entity 'preprint' named entity 'IL-10' named entity 'COVID' named entity 'immunomodulatory' named entity 'H1N1' named entity '10.7' named entity 'design of the study' named entity 'treatment protocol' named entity 'medRxiv' named entity 'Western medicine' named entity 'IL-6' named entity 'fever' named entity 'cytokine' named entity 'preprint' named entity 'medRxiv'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software